Mahmut Gumus, MD, et al. SELECT: A Phase 2 Randomized Trial Evaluating 2 doses of Vopratelimab + Pimivalimab in TISvopra Selected Patients. Presented at ESMO IO December 2022
Contact Us
Jounce Therapeutics, Inc.
780 Memorial Drive
Cambridge, MA 02139
Phone: (857) 259-3840
Fax: (888) 459-2940
For Investor and Media inquiries, please contact:
Eric Laub
(857) 259-3853 elaub@jouncetx.com